World Generic Markets(WGM)

BMI View: This FY13 report shows that final settlement agreements are on an upward trend, but those with potential pay-for-delay implications are currently falling. The report acts as an annual barometer for current legal thinking on the issue; the lack of a clear trend reflects fluctuating legal opinions. The FY14 report will show more fully the impact of the Supreme Court ruling in 2013 on pay-for-delay agreements.

Table of Contents

Editor's Note

• Despite Overall Upward Trend, FTC Report Shows Fluctuations In Settlement Agreements

Americas

Chile

• Company News
  • Abbott Completes Acquisition Of CFR

USA

• Company News
  • Fosun To Invest In Amerigen
  • Actavis Launches US Generic Speciality Injectable Portfolio

• Patent & Litigation News
  • Helsinn Reaches Palonosetron Settlement With Sandoz
  • Sunovion Files Lurasidone Patent Infringement Lawsuits
  • Actavis Challenges US Abstral Patents
  • Akorn Initiates Difluprednate Patent Challenge
  • Mounting Patent Challenges Will Determine Supernus' Financial Rewards

• Product Updates
  • Mylan Launches Valsartan In US
  • US Approval Of Sandoz' Filgrastim Advances With Small Steps, Not Giant Leaps
  • Colchicine Marketing Battle To Re-Emerge In US
  • Perrigo Launches Testosterone Gel In US
  • Hospira Files US Epoetin Alfa Biosimilar Application
  • Perrigo Launches Clobetasol Spray In US
  • Jubilant Gains US Mycophenolate And Rizatriptan Approvals
  • Mylan Launches Lamivudine In US
  • Elite Commences Isradipine Shipments
  • Akorn Gains US Phenylephrine Ophthalmic Solution Approval

Europe

UK

• Regulatory News
  • NICE Updates Biosimilars Guidance

Asia/Pacific

India

• Patent & Litigation News
  • Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm

Singapore

• Company News
  • Strides' Singapore Subsidiary Gains International Headquarters Status